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Summary
Background: There have been few reports that have analyzed the predictive factors for heart
failure death, which is sub-divided into pump failure death and sudden cardiac death, in the
long term.
Methods and results: We followed 186 consecutive patients with myocardial infarction (MI) and
115 consecutive patients with non-ischemic heart failure (NIHF) during 73± 3 months. In the MI
group, 26 died from pump failure and 12 died from sudden cardiac death. In the NIHF group, 21
died from pump failure and 9 died from sudden cardiac death. Multivariate analysis revealed
that the log B-type natriuretic peptide (BNP) was an independent predictor for pump failure
death in both groups. In the MI group, the estimated glomerular ﬁltration rate (eGFR) was an
independent predictor for sudden cardiac death. Kaplan—Meier analysis revealed that a high
BNP level was a risk factor for pump failure death in either MI or NIHF patients. On the other
hand, the sudden cardiac death rate was signiﬁcantly higher in the MI patients with low eGFR
than in those with high eGFR.
∗ Corresponding author. Tel.: +81 96 373 5175; fax: +81 96 362 3256.
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Conclusions: The plasma BNP level is an independent predictor for pump failure death in both MI
is an independent predictor for sudden cardiac death in MI patients.
ardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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eart failure is an important leading cause of morbidity and
ortality [1]. Because many patients who die due to heart
ailure have myocardial dysfunction, such as myocardial
nfarction (MI) or non-ischemic heart failure (NIHF), prog-
ostic factors for these diseases have been the subject of
umerous investigations worldwide. Recently, B-type natri-
retic peptide (BNP) has been recognized as a diagnostic
arker in patients with myocardial dysfunction.
We previously reported that BNP is mainly secreted from
he heart in patients with heart failure [2—4]; furthermore,
hat BNP secretion levels from the heart increase in pro-
ortion to the severity of heart failure [2—4]. Secretion
f BNP from the heart is induced by mechanical stress
n cardiomyocytes [5]. Cytokines, including interleukin-
, cardiotrophine I, and leukemia inhibitory factor (LIF),
lso induce BNP secretion [6—8]. Further, oxidative stress
nduces the secretion of BNP, via the re-expression of fatal
ene programs and the apoptosis process in cardiomyocytes
9].
Plasma levels of BNP are able to be used as a marker
f the degree of myocardial dysfunction in patients with
cute myocardial infarction (AMI) [3,10,11]. We previously
eported that plasma BNP levels rapidly and markedly
ncrease after the onset of AMI. Plasma BNP levels decrease
ithin 48 h from the onset of AMI, and thereafter the plasma
NP levels increase again after several days in AMI patients
ith severe anterior MI [10]. The time course of the plasma
NP levels shows a distinct pattern with two peaks. The
echanism for the formation of the ﬁrst peak is consid-
red to be an acute-phase reactant in response to acute
issue injuries, including mechanical stress, cytokines, and
xidative stress. The mechanisms for the formation of the
econd peak are considered to be myocardial expansion and
ubsequent ventricular remodeling. Many MI patients with
igh plasma BNP levels at the second peak have large infarct
izes, and so they also have high plasma BNP levels in the
hronic phase [10]. We previously reported that plasma BNP
evel in the chronic phase is an independent predictor for
ardiac death in patients with AMI [12].
It has been reported that the plasma BNP levels in the
table phase are more useful as predictive factors for mor-
idity and mortality in patients with heart failure than the
lasma BNP levels in the acute phase [13]; however, there
ave been few long-term follow-up studies done to investi-
ate prognostic values, including evaluating the plasma BNP
evels at the stable phase in patients with heart failure.
e began to measure plasma BNP levels from 1990 afterhe initial discovery of BNP, and a novel antibody for BNP
as created by our research group shortly thereafter [4,14].
esides plasma BNP levels, many other variables including
nemia, renal dysfunction, low blood pressure, low body
ass index, and male sex have been reported to be prog-
D
I
fostic predictive factors for cardiac death in heart failure
atients [15—18].
The aim of this study was to investigate the long-term
rognostic predictive factors, including the clinical charac-
eristics and plasma BNP levels, in patients with MI or in
hose with NIHF.
ethods
tudy patients
he study recruitment began in January 1990 and ended in
ecember 2004. The ﬁnal follow-up date was November 1,
007. During this period, there were 942 admitted patients
ith MI or NIHF. In these patients, we were ultimately able
o follow up 301 patients for whom highly reliable informa-
ion was available about their prognoses from their afﬁliated
ospitals. The present study included 186 patients with MI
nd 115 patients with NIHF.
Inclusion criteria for patients with MI were as follows: (1)
linical symptoms, including ST changes or a new left bundle
ranch block, and an elevation of serum creatine kinase-
B isoenzyme level to more than twice the normal upper
evel; (2) development of pathological Q waves with or with-
ut symptoms; or, (3) region of loss of viable myocardium
hat is thinned and fails to contract, in the absence of a
on-ischemic cause. Inclusion criteria for patients with NIHF
ere as follows: (A) negative ﬁndings for coronary artery dis-
ase utilizing coronary arteriography; (B) negative ﬁndings
or primary valvular heart disease utilizing echocardiogra-
hy; (C) global left ventricular dysfunction with an ejection
raction of less than 60% and (D) history of heart failure (New
ork Heart Association class II to IV).
All clinical causes of myocardial dysfunction were
btained from the hospital charts. End points of this study
ere deﬁned as cardiac death, including pump failure or
udden cardiac death. Deaths resulting from a deterioration
f congestive heart failure, with progression of conges-
ive symptoms, were classiﬁed as pump failure. Sudden
ardiac death was deﬁned as witnessed cardiac arrest or
eath within 1 h after the onset of acute symptoms or as
n unexpected, unwitnessed death (i.e. during sleep). Non-
ardiac death was deﬁned as survivors, including patients,
ho died from other causes. The protocol was in agree-
ent with our institutional review boards and as publishedata collection
n the present study, we obtained blood samples and per-
ormed physical examinations, including body mass index,
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mean blood pressure, and heart rate at the stable phase
(3—4 weeks after admission).
Measurement of plasma BNP levels
The plasma BNP concentration levels were measured utiliz-
ing a speciﬁc radioimmunoassay for human BNP from 1990
to 1993. A speciﬁc immunoradiometric assay for human BNP
was utilized from 1993 (Shionoria BNP; Shionogi Inc., Osaka,
Japan). There were no signiﬁcant differences in the BNP
values obtained by the radioimmunoassay and immunora-
diometric assay methods [19].
Measurement of estimated glomerular ﬁltration
rate
Measuring estimated glomerular ﬁltration rate (eGFR) is
considered the most suitable method for quantifying renal
function [20]. The eGFR was assessed using the 4 component
Modiﬁcation of Diet in Renal Disease Equation, incorpo-
rating age, race, gender, and serum creatinine level. The
Japan Chronic Kidney Disease Initiative has found an equa-
tion for accurate GFR estimation in Japanese people: eGFR
in Japanese (in ml/min/1.73m2) = 0.741× 175× [serum cre-
atinine level (in mg/dl)]−1.154 × [age (in year)]−0.203 [20]. The
Japanese Society of Nephrology has recommended using this
equation to measure GFR in Japanese [20]. Because all of
the study patients were Japanese, we used this equation to
measure eGFR.
Statistical analysis
Continuous values are expressed as the mean± SD. A Cox
proportional hazards regression analysis was performed to
identify independent predictors for pump failure death and
sudden cardiac death including the following variables: age,
gender body mass index, current smoking, history of hyper-
tension, history of diabetes mellitus, history of dyslipidemia,
atrial ﬁbrillation, mean blood pressure, heart rate, log
BNP, eGFR and the following clinical laboratory data: white
blood cell count, hemoglobin levels, serum uric acid levels,
serum sodium, and serum potassium levels. The plasma BNP
level was not normally distributed, so we selected normally
distributed log BNP for analysis. When we evaluated the
prognosis for pump failure death, we excluded the sudden
cardiac death patients. When we evaluated the prognosis for
sudden cardiac death, we excluded the pump failure death
patients. We set out a cut-off point to determine a patient
group with a low risk of cardiac death. Kaplan—Meier sur-
vival curves were used for survival comparisons between the
patient groups stratiﬁed according to this cut-off point. Sta-
tistical signiﬁcance was deﬁned as a probability value <0.05.
ResultsFollow-up periods
For all study patients, the mean follow-up period was 74
months (range 1—215 months), with a mean follow-up period
of 51± 6 months (range 1—191 months) for the cardiac death
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roup and 80± 4 months (range 1—215 months) for the non-
ardiac death group.
linical characteristics
he clinical characteristics in the MI, NIHF, and total groups
re shown in Table 1. The mean ages in the MI, NIHF, and total
roups were 67.8± 10.7, 56.2± 14.3, and 63.4± 13.4 years,
espectively. The MI patients were signiﬁcantly older than
he NIHF patients (p < 0.05). The mean levels of left ventric-
lar ejection fraction (LVEF) in the MI, NIHF, and total groups
ere 51.4± 17.0%, 34.5± 13.3%, and 49.9± 17.7%, respec-
ively. The LVEF was signiﬁcantly higher in the MI group
han in the NIHF group (p < 0.05). The incidence of diabetes
ellitus and dyslipidemia was signiﬁcantly higher in the MI
roup than in the NIHF group. The incidence of atrial ﬁb-
illation was signiﬁcantly lower in the MI group than in the
IHF group. The prescription rates of angiotensin-converting
nzyme inhibitors, digitalis, furosemide, and spironolactone
ere signiﬁcantly lower in the MI group than in the NIHF
roup (p < 0.003). On the other hand, calcium-channel block-
rs and statins were prescribed more often in the MI group
han in the NIHF group (p < 0.005). There were no signiﬁcant
ifferences in prescription rates of angiotensin II receptor
lockers and -blockers between the MI group and the NIHF
roup.
rognosis of patients and causes of death
n the MI group, 136 survived and 50 died during the study
eriod. Out of the 50 patients who died, 26 (52%) died from
ump failure, 12 (24%) died from sudden cardiac death, and
2 (24%) died from other causes: 7 (14%) with malignant
isease, 3 (6%) with pneumonia, 1 (2%) with sepsis and 1
2%) with senility.
In the NIHF group, 76 survived and 39 died during the
tudy period. Out of the 39 patients who died, 21 (68%) died
rom pump failure, 9 (23%) died from sudden cardiac death,
nd 9 (24%) died from other causes: 1 (3%) with malignant
isease, 4 (10%) with pneumonia, 2 (5%) with cerebral infarc-
ion, 1 (3%) with cerebral hemorrhage and, 1 (3%) with liver
ysfunction.
nivariate and multivariate analysis for predictors
f cardiac death
I group
he results of univariate and multivariate analyses in the MI
roup are shown in Table 2.
According to the univariate analysis, eGFR, serum uric
cid levels, serum potassium levels, and log BNP were sig-
iﬁcant predictive factors for cardiac death in the MI group.
ubsequently, we examined multivariate analysis using age,
eart rate, eGFR, serum uric acid levels, serum potassium
evels, and log BNP, for which p-values were less than 0.1.
ultivariate analysis revealed that log BNP was an indepen-
ent predictor for cardiac death in the MI group [HR 4.01
1.62—9.92), p = 0.0060]. The univariate analysis revealed
hat hemoglobin level, eGFR, serum uric acid level, and
og BNP were signiﬁcant predictive factors for pump failure
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Table 1 Clinical characteristics.
MI group (n = 186) NIHF group (n = 115) Total group (n = 301)
Age (years) 67.8± 10.7 56.2± 14.3* 63.4± 13.4
Male 67% (124/186) 69% (79/115) 67% (203/301)
LVEF (%) 51.4± 17.0 34.5± 13.3* 44.9± 17.7
Current smoking 52% (97/186) 44% (51/115) 49% (148/301)
Hypertension 42% (78/186) 31% (35/114) 38% (113/300)
Diabetes mellitus 39% (72/186) 18% (20/114)* 31% (92/300)
Dyslipidemia 47% (87/186) 25% (28/114)* 38% (115/300)
Atrial ﬁbrillation 5% (10/186) 22% (25/115)* 12% (35/301)
ICD 1% (2/186) 1% (1/115) 1% (3/301)
Dialysis 1% (1/186) 1% (1/115) 1% (2/301)
Pharmacotherapy
ACEI 51% (95/185) 85% (98/115)* 64% (193/300)
ARB 13% (24/185) 19% (22/115) 15% (46/300)
Digitalis 3% (5/185) 20% (23/115)* 9% (28/300)
Furosemide 27% (50/185) 48% (55/115)* 35% (105/300)
Spironolactone 11% (20/185) 24% (28/115)* 16% (48/300)
Calcium-channel blockers 75% (139/185) 9% (10/115)** 50% (149/300)
Nitrate 53% (98/185) 6% (7/115) 35% (105/300)
-Blockers 26% (48/185) 28% (32/115) 27% (80/300)
Statins 32% (59/185) 17% (19/115) 26% (78/300)
MI, myocardial infarction; NIHF, non-ischemic heart failure; LVEF, left ventricular ejection fraction; ICD, implanted cardiac deﬁbrillator;
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers.
* p < 0.05 vs MI group.
** p < 0.01 vs MI group.
Table 2 Predictive factors in myocardial infarction patients.
Cardiac death (pump failure death + sudden
cardiac death)
Pump failure death Sudden cardiac death
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) P-value HR (95% CI) p-Value HR (95% CI) p-Value
Age (per year) 1.03 0.0971 1.01 0.7701 1.02 0.3098 1.05 0.1238
(1.00—1.07) (0.96—1.06) (0.98—1.06) (0.99—1.12)
Male (+) 0.72 0.3669 0.99 0.9728 0.18 0.1021
(0.35—1.48) (0.44—2.22) (0.02—1.41)
BMI (per 1 kg/m2) 1.04 0.4659 1.03 0.6702 1.08 0.4386
(0.93—1.16) (0.90—1.17) (0.89—1.32)
Current smoking (+) 0.96 0.9056 0.97 0.9459 0.84 0.7656
(0.51—1.83) (0.45—2.11) (0.27—2.65)
Hypertension (+) 1.28 0.4771 1.50 0.3456 0.96 0.9462
(0.65—2.51) (0.65—3.46) (0.30—3.07)
Mean blood
pressure (per
1mmHg)
0.99 0.5429 0.98 0.2168 1.02 0.3673
(0.97—1.02) (0.96—1.01) (0.98—1.06)
Diabetes mellitus
(+)
0.82 0.5405 0.79 0.5486 0.88 0.8298
(0.43—1.56) (0.36—1.72) (0.28—2.79)
Dyslipidemia (+) 1.20 0.5841 1.23 0.6047 1.27 0.6812
(0.63—2.28) (0.56—2.68) (0.40—4.01)
Heart rate (per
1 beat/min)
1.02 0.051 1.01 0.5961 1.02 0.1419 1.02 0.1681
(1.00—1.04) (0.96—1.06) (1.00—1.04) (0.99—1.06)
Atrial ﬁbrillation (+) 0.67 0.5912 0.49 0.3450 ··· ···
(0.16—2.85) (0.11—2.14)
WBC (per
1 count/l)
1 0.5616 1 0.2205 1.00 0.4188
(1.00—1.00) (1.00—1.00) (1.00—1.00)
Hemoglobin level
(per 1 g/dl)
0.89 0.1435 0.82 0.0296 0.87 0.2493 1.14 0.4732
(0.76—1.04) (0.68—0.98) (0.69—1.10) (0.80—1.62)
eGFR (per
1ml/min/1.73m2)
0.96 <0.0001 0.98 0.1800 0.96 0.0005 0.99 0.4592 0.95 0.0034 0.96 0.0211
(0.95—0.98) (0.96—1.01) (0.94—0.98) (0.96—1.02) (0.93—0.99) (0.93—0.99)
Serum uric acid
level (per
1mg/dl)
1.45 0.0007 1.16 0.2550 1.49 0.0019 1.31 0.1103 1.39 0.1128
(1.17—1.80) (0.90—1.51) (1.16—1.91) (0.94—1.81) (0.93—2.10)
Serum sodium level
(per 1mequiv./l)
0.95 0.3542 0.92 0.2336 1.02 0.8697
(0.85—1.06) (0.81—1.05) (0.83—1.25)
Serum potassium
level (per
1mequiv./l)
2.03 0.0453 0.81 0.6164 2.06 0.0872 0.78 0.6310 2.20 0.1887
(1.02—4.05) (0.36—1.82) (0.90—4.74) (0.29—2.11) (0.68—7.15)
Log BNP [per
1 log (pg/ml)]
5.70 <0.0001 4.01 0.0060 8.98 <0.0001 3.64 0.0335 3.03 0.0678 1.66 0.3633
(2.65—12.24) (1.62—9.92) (3.36—23.99) (1.11—11.95) (0.92—9.97) (0.56—4.99)
HR, hazard ratio; CI, conﬁdence interval; BMI, body mass index; WBC, white blood cell; eGFR, estimated glomerular ﬁltration rate; BNP, B-type natriuretic peptide.
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Table 3 Predictive factors in non-ischemic heart failure patients.
Cardiac death (pump failure death + sudden cardiac
death)
Pump failure death Sudden cardiac death
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis Univariate analysis
HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
Age (per year) 1.01 0.4825 1.01 0.4663 1.01 0.7456
(0.98—1.04) (0.98—1.04) (0.96—1.06)
Male (+) 1.27 0.526 1.44 0.4225 1.02 0.9814
(0.60—2.68) (0.59—3.47) (0.25—4.09)
BMI (per 1 kg/m2) 0.93 0.1615 0.86 0.0167 1.05 0.6134 1.05 0.5078
(0.84—1.03) (0.75—0.97) (0.86—1.29) (0.91—1.21)
Current smoking (+) 1.33 0.4542 1.33 0.5296 1.46 0.5905
(0.63—2.81) (0.55—3.23) (0.37—5.87)
Hypertension (+) 1.84 0.2178 2.31 0.1825 1.44 0.6505
(0.70—4.84) (0.67—7.93) (0.30—7.02)
Mean blood pressure
(per 1mmHg)
0.97 0.015 0.98 0.0984 0.96 0.0048 0.97 0.0645 0.99 0.657
(0.95—0.995) (0.95—1.004) (0.93—0.99) (0.93—1.00) (0.96—1.03)
Diabetes mellitus (+) 0.94 0.9084 1.34 0.6995 0.58 0.5066
(0.32—2.73) (0.31—5.82) (0.12—2.88)
Dyslipidemia (+) 1.59 0.3886 2.37 0.2475 0.93 0.9314
(0.55—4.60) (0.55—10.26) (0.19—4.57)
Heart rate (per
1 beat/min)
0.99 0.3538 0.99 0.2521 1.00 0.9995
(0.98—1.01) (0.97—1.01) (0.98—1.03)
Atrial ﬁbrillation (+) 1.34 0.5246 1.49 0.5233 1.19 0.827
(0.55—3.28) (0.48—4.27) (0.25—5.75)
WBC (per 1 count/l) 1.00 0.5099 1.00 0.1588 1.00 0.3029
(1.00—1.00) (1.00—1.00) (0.999—1.00)
Hemoglobin level (per
1 g/dl)
0.90 0.1832 0.78 0.0045 0.82 0.154 1.36 0.0951
(0.77—1.05) (0.65—0.93) (0.62—1.08) (0.95—1.94)
eGFR (per
1ml/min/1.73m2)
0.98 0.0435 0.99 0.1737 0.98 0.048 0.99 0.702 0.99 0.3038
(0.97—0.999) (0.97—1.006) (0.96—1.00) (0.96—1.02) (0.96—1.01)
Serum uric acid level
(per 1mg/dl)
1.05 0.5838 1.12 0.2837 0.88 0.5149
(0.88—1.26) (0.91—1.37) (0.60—1.30)
Serum sodium level
(per 1mequiv./l)
0.95 0.3463 0.93 0.2061 1.02 0.8406
(0.86—1.05) (0.83—1.04) (0.81—1.29)
Serum potassium level
(per 1mequiv./l)
0.92 0.8131 1.31 0.5287 0.37 0.1468
(0.44—1.90) (0.56—3.06) (0.09—1.42)
5.26
(2.2
eGFR,
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oLog BNP [per 1 log
(pg/ml)]
3.68 0.0003 4.77 0.0005
(1.83—7.39) (1.98—11.49)
HR, hazard ratio; CI, conﬁdence interval; BMI, body mass index; WBC, white blood cell;
death in the MI group. Subsequently, we examined multi-
variate analysis using hemoglobin level, eGFR, serum uric
acid level, serum potassium level, and log BNP, for which
p-values were less than 0.1. Multivariate analysis revealed
that log BNP was an independent predictor for pump failure
death in the MI group [HR 3.64 (1.11—11.95), p = 0.0335].
The univariate analysis revealed that eGFR was a signiﬁcant
predictive factor for sudden cardiac death in the MI group.
Subsequently, we examined multivariate analysis using eGFR
and log BNP, for which p-values were less than 0.1. Mul-
tivariate analysis revealed that eGFR was an independent
predictor for sudden cardiac death in the MI group [HR 0.96
(0.93—0.99), p = 0.0211].
NIHF group
The results of univariate and multivariate analyses in the
NIHF group are shown in Table 3. According to the uni-
variate analysis, mean blood pressure, eGFR, and log BNP
were signiﬁcant predictive factors for cardiac death in the
NIHF group. Subsequently, we examined multivariate analy-
sis using mean blood pressure, eGFR and log BNP, for which
p-values were less than 0.1. Multivariate analysis revealed
that log BNP was an independent predictor for cardiac death
in the NIHF group [HR 4.77 (1.98—11.49), p = 0.0005]. The
univariate analysis revealed that body mass index, mean
blood pressure, hemoglobin level, eGFR, and log BNP were
signiﬁcant predictive factors for pump failure death in the
NIHF group. Subsequently, we examined multivariate anal-
ysis using mean blood pressure, hemoglobin level, eGFR,
K
W
c
a0.0001 7.65 0.0032 2.14 0.1947
4—12.34) (1.98—29.56) (0.68—6.79)
estimated glomerular ﬁltration rate; BNP, B-type natriuretic peptide.
nd log BNP, for which p-values were less than 0.1. Multi-
ariate analysis revealed that log BNP was an independent
redictor for pump failure death in the NIHF group [HR 7.65
1.98—29.56), p = 0.0032]. There were no signiﬁcant predic-
ive factors found utilizing both univariate and multivariate
nalyses for sudden cardiac death in the NIHF group.
eceiver operating characteristic analysis
e examined the sensitivity and speciﬁcity of various cut-
ff values of independent predictive factors for predicting
urvival and created receiver operating characteristic (ROC)
urves. In the MI group, the cut-off values determined by
OC curve analysis were 2.36 of log BNP, equivalent to a
NP level of 230 pg/ml for cardiac death (Fig. 1a), 2.36 of
og BNP, equivalent to a BNP level of 230 pg/ml for pump
ailure death (Fig. 1b), and 54.2ml/min/1.73m2 of eGFR
or sudden cardiac death (Fig. 1c). In the NIHF group, the
ut-off values determined by ROC curve analysis were 2.28
f log BNP, equivalent to a BNP level of 191 pg/ml for cardiac
eath (Fig. 2a) and 2.28 of log BNP, equivalent to a BNP level
f 191 pg/ml for pump failure death (Fig. 2b).aplan—Meier survival analysis
e separated each group into two sub-groups based on their
ut-off values which were determined by ROC curve analysis,
nd examined the Kaplan—Meier survival analysis.
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Figure 1 The receiver operating characteristics (ROC) curves of predictive factors for myocardial infarction (MI) patients. (a) ROC
curve of log B-type natriuretic peptide (BNP) for MI patients with cardiac death. Area under the curve (AUC) was 67.3%, sensitivity
was 54.5% and speciﬁcity was 74.3%. The cut-off value of log BNP was 2.36, equivalent to a BNP level of 230 pg/ml. (b) ROC curve
of log BNP for MI patients with pump failure death. AUC was 71.7%, sensitivity was 59.1% and speciﬁcity was 74.3%. The cut-off
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talue of log BNP was 2.36, equivalent to a BNP level of 230 pg/m
I patients with sudden cardiac death. AUC was 70.4%, sensitiv
as 54.2ml/min/1.73m2.
In the MI patients, the occurrence of cardiac death was
igniﬁcantly higher in the patients with high BNP levels than
n those with low BNP levels (p < 0.0001) (Fig. 3a). The occur-
ence of pump failure death was signiﬁcantly higher in the
atients with high BNP levels than in those with low BNP
evels (p < 0.0001) (Fig. 3b). The occurrence of sudden car-
iac death was signiﬁcantly higher in the patients with low
GFR levels than in those with high eGFR levels (p < 0.0001)
Fig. 3c).
In the NIHF patients, the occurrence of cardiac death
as signiﬁcantly higher in the patients with high BNP levels
han in those with low BNP levels (p = 0.0002) (Fig. 4a). The
ccurrence of pump failure death was signiﬁcantly higher in
n
b
f
a
dc) ROC curve of estimated glomerular ﬁltration rate (eGFR) for
as 63.4% and speciﬁcity was 83.3%. The cut-off value of eGFR
he patients with high BNP levels than in those with low BNP
evels (p < 0.0001) (Fig. 4b).
iscussion
lthough the diagnostic value of measuring plasma BNP
evels has been established in patients with cardiac dysfunc-
ion, there have been few reports investigating the prog-
ostic value of it in the long term; furthermore, there have
een few reports analyzing the predictive factors for heart
ailure death, which is sub-divided into pump failure death
nd sudden cardiac death. In the present study, we sub-
ivided the heart failure patients who died into two groups:
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Figure 2 The receiver operating characteristics (ROC) curves of predictive factors for non-ischemic heart failure (NIHF) patients.
(a) ROC curve of log B-type natriuretic peptide (BNP) for NIHF patients with cardiac death. Area under the curve (AUC) was 73.7%,
sensitivity was 69.0% and speciﬁcity was 70.1%. The cut-off value of log BNP was 2.28, equivalent to a BNP level of 191 pg/ml. (b)
ROC curve of log BNP for NIHF patients with pump failure death. AUC was 78.7%, sensitivity was 80.0% and speciﬁcity was 70.1%.
The cut-off value of log BNP was 2.28, equivalent to a BNP level of 191 pg/ml.
Figure 3 Kaplan—Meier survival curves of cumulative survival rates in patients with myocardial infarction (MI). (a) Kaplan—Meier
survival curves of cumulative non-cardiac death rates in patients with MI divided into two sub-groups according to their log B-type
natriuretic peptide (BNP) values. (b) Kaplan—Meier survival curves of cumulative non-pump failure death rates in patients with MI
divided into two sub-groups according to their log BNP values. (c) Kaplan—Meier survival curves of cumulative non-sudden cardiac
death rates in patients with MI divided into two sub-groups according to their estimated glomerular ﬁltration rate (eGFR) values.
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Figure 4 Kaplan—Meier survival curves of cumulative survival rates in patients with non-ischemic heart failure (NIHF). (a)
Kaplan—Meier survival curves of cumulative non-cardiac death rates in patients with NIHF divided into two sub-groups accord-
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Cng to their log B-type natriuretic peptide (BNP) values. (a) Ka
ates in patients with NIHF divided into two sub-groups accordi
hose with pump failure death and those with sudden car-
iac death. Herein we investigated the prognostic predictive
actors for pump failure death and sudden cardiac death, in
he MI patients and in the NIHF patients: furthermore, we
etermined cut-off values which can be used for prognostic
redictive factors.
In the MI group, a plasma BNP level was the only indepen-
ent prognostic predictive factor for pump failure death.
e determined that the best cut-off value of plasma BNP
evel for predicting morbidity and mortality was 230 pg/ml.
his plasma BNP level dovetails neatly with previous reports
12,21]. Out of 38 cardiac death patients, 12 patients died
rom sudden cardiac death in the MI group, eGFR was
he only independent predictive factor for sudden car-
iac death. We decided that the best cut-off value of
GFR was 54.2ml/min/1.73m2. Recent studies have shown
n association between progressive chronic kidney disease
nd cardiovascular morbidity and mortality [16,22]. The
ccurrence of malignant arrhythmia, including ventricular
achycardia and ventricular ﬁbrillation, is high in end-stage
enal failure patients because of cardiac hypertrophy and/or
ardiac ﬁbrosis [23,24]. Components of autonomic dysfunc-
ion and altered electrolyte metabolism have also been
uggested to contribute to a risk of malignant arrhythmia
25,26]. Previous studies have shown a signiﬁcant associa-
ion between sudden cardiac death and renal dysfunction in
I patients with severe cardiac dysfunction (left ventricu-
ar ejection fraction ≤30%) [27]. In the present long-term
ollow-up study, we found that mild to severe renal dys-
unction was a signiﬁcant prognostic predictive factor for
udden cardiac death in consecutive MI patients who had
ild to severe cardiac dysfunction; therefore, we recom-
end that patients with MI and renal dysfunction (eGFR
54.2ml/min/1.73m2) should be treated much more care-
ully by clinicians.Up until now, there have been no long-term follow-up
tudies to investigate plasma BNP levels in patients with
IHF. In the NIHF patients, the plasma BNP level was the only
igniﬁcant independent predictor for pump failure death.
e decided that the best cut-off value for plasma BNP level
A
f
i
d—Meier survival curves of cumulative non-pump failure death
their log BNP values.
n the pump failure death patients was 191 pg/ml. The cut-
ff value of log BNP for predicting morbidity and mortality
as higher in patients with MI than in those with NIHF.
ecretion levels of BNP from cardiomyocytes are induced
y hypertrophy, mechanical stress, cytokines, and/or oxida-
ive stress. In a heart undergoing MI, myocardial hypertrophy
s induced in the non-infarct myocytes, especially in the
yocytes around the infarction site [28]. The myocytes also
ustain mechanical stress. Around the infarction site, we can
ee abundant inﬂammatory cells which produce abundant
ytokines and oxidative stress. These above results possibly
how the reason why the plasma BNP levels in MI patients
re higher than in NIHF patients and why the cut-off value
f log BNP for predicting morbidity and mortality was higher
n patients with MI than in those with NIHF. We recommend
hat an effort should be made to control the plasma BNP
evel in MI patients but more rigorously in NIHF patients.
There were no signiﬁcant predictive factors for sud-
en cardiac death in the NIHF group among the variables
hat we utilized in this study. Almost all NIHF patients in
he present study presented with dilated cardiomyopathy
DCM).
DCM is recognized as a heritable disorder, especially in
atients with malignant arrhythmia [29]. Mutations in genes
elated to cytoskeletal [30], contractile [31], nuclear mem-
rane [32], and other [33] proteins have been identiﬁed in
atients with familial or sporadic DCM. There are possibly
enetic factors which predispose the patients to cardiac
udden death due to their malignant arrhythmia. Further
esearch, using a larger and genetic clinical study, is neces-
ary to clarify the signiﬁcant predictive factors for cardiac
udden death in NIHF patients.
onclusionplasma BNP level is a signiﬁcant independent predictive
actor for pump failure death in MI and NIHF patients. eGFR
s a signiﬁcant independent predictive factor for sudden car-
iac death in MI patients.
[[
[
[
[
[
[
[
[
[
[
[
[
[
[Prognostic factors of heart failure
References
[1] Jessup M, Brozena S. Heart failure. N Engl J Med
2003;348:2007—18.
[2] Yasue H, Obata K, Okumura K, Kurose M, Ogawa H, Mat-
suyama K, Jougasaki M, Saito Y, Nakao K, Imura H. Increased
secretion of atrial natriuretic polypeptide from the left ven-
tricle in patients with dilated cardiomyopathy. J Clin Invest
1989;83:46—51.
[3] Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K,
Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K.
Localization and mechanism of secretion of B-type natriuretic
peptide in comparison with those of A-type natriuretic peptide
in normal subjects and patients with heart failure. Circulation
1994;90:195—203.
[4] Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y,
Shirakami G, Jougasaki M, Obata K, Yasue H, Kambayashi Y,
Inouye K, Imura H. Brain natriuretic peptide as a novel cardiac
hormone in humans. Evidence for an exquisite dual natriuretic
peptide system, atrial natriuretic peptide and brain natriuretic
peptide. J Clin Invest 1991;87:1402—12.
[5] Bruneau BG, Piazza LA, de Bold AJ. BNP gene expression is
speciﬁcally modulated by stretch and ET-1 in a new model of
isolated rat atria. Am J Physiol 1997;273(6 Pt 2):H2678—86.
[6] Harada E, Nakagawa O, Yoshimura M, Harada M, Nakagawa M,
Mizuno Y, Shimasaki Y, Nakayama M, Yasue H, Kuwahara K, Saito
Y, Nakao K. Effect of interleukin-1 beta on cardiac hypertro-
phy and production of natriuretic peptides in rat cardiocyte
culture. J Mol Cell Cardiol 1999;31:1997—2006.
[7] Kuwahara K, Saito Y, Harada M, Ishikawa M, Ogawa E, Miyamoto
Y, Hamanaka I, Kamitani S, Kajiyama N, Takahashi N, Naka-
gawa O, Masuda I, Nakao K. Involvement of cardiotrophin-1
in cardiac myocyte—nonmyocyte interactions during hypertro-
phy of rat cardiac myocytes in vitro. Circulation 1999;100:
1116—24.
[8] Nakaoka Y, Nishida K, Fujio Y, Izumi M, Terai K, Oshima
Y, Sugiyama S, Matsuda S, Koyasu S, Yamauchi-Takihara K,
Hirano T, Kawase I, Hirota H. Activation of gp130 transduces
hypertrophic signal through interaction of scaffolding/docking
protein Gab1 with tyrosine phosphatase SHP2 in cardiomy-
ocytes. Circ Res 2003;93:221—9.
[9] Hare JM. Oxidative stress and apoptosis in heart failure pro-
gression. Circ Res 2001;89:198—200.
[10] Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Mat-
sumura T, Mukoyama M, Nakao K. Increased plasma levels of
brain natriuretic peptide in patients with acute myocardial
infarction. Circulation 1993;88:82—91.
[11] Sumida H, Yasue H, Yoshimura M, Okumura K, Ogawa H,
Kugiyama K, Matsuyama K, Kikuta K, Morita E, Nakao K.
Comparison of secretion pattern between A-type and B-type
natriuretic peptides in patients with old myocardial infarction.
J Am Coll Cardiol 1995;25:1105—10.
[12] Suzuki S, Yoshimura M, Nakayama M, Mizuno Y, Harada E, Ito
T, Nakamura S, Abe K, Yamamuro M, Sakamoto T, Saito Y,
Nakao K, Yasue H, Ogawa H. Plasma level of B-type natriuretic
peptide as a prognostic marker after acute myocardial infarc-
tion: a long-term follow-up analysis. Circulation 2004;110:
1387—91.
[13] Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui
T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M. High
levels of plasma brain natriuretic peptide and interleukin-6
after optimized treatment for heart failure are indepen-
dent risk factors for morbidity and mortality in patients
with congestive heart failure. J Am Coll Cardiol 2000;36:
1587—93.
[14] Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic
peptide in porcine brain. Nature 1988;332:78—81.
[63
15] Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common
in heart failure and is associated with poor outcomes: insights
from a cohort of 12 065 patients with new-onset heart failure.
Circulation 2003;107:223—5.
16] Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kid-
ney disease and the risks of death, cardiovascular events, and
hospitalization. N Engl J Med 2004;351:1296—305.
17] Cleland JG, Dargie HJ, Ford I. Mortality in heart failure:
clinical variables of prognostic value. Br Heart J 1987;58:
572—82.
18] Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali
H, Pfeffer MA, Yusuf S, Swedberg K, Michelson EL, Granger
CB, McMurray JJ, Solomon SD, CHARM Investigators. Body mass
index and prognosis in patients with chronic heart failure:
insights from the Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity (CHARM) program. Circu-
lation 2007;116:627—36.
19] Yasue H, Yoshimura M, Jougasaki M, Itoh H, Suga S, Ogawa Y,
Nakao K. Plasma levels of brain natriuretic peptide in normal
subjects and patients with chronic congestive heart failure:
measurement by immunoradiometric assay (IRMA). Horm Clin
1993;41:397—403.
20] Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S,
Makino H, Hishida A, Matsuo S. Modiﬁcation of the Modiﬁcation
of Diet in Renal Disease (MDRD) Study equation for Japan. Am
J Kidney Dis 2007;50:927—37.
21] Richards AM, Nicholls MG, Espiner EA, Lainchbury JG,
Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG,
Yandle TG. B-type natriuretic peptides and ejection frac-
tion for prognosis after myocardial infarction. Circulation
2003;107:2786—92.
22] Matsuo K, Inoue T, Node K. Estimated glomerular ﬁltration rate
as a predictor of secondary outcomes in Japanese patients with
coronary artery disease. J Cardiol 2009;53:232—9.
23] Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse
intermyocardiocytic ﬁbrosis in uraemic patients. Nephrol Dial
Transplant 1990;5:39—44.
24] Levin A, Singer J, Thompson CR, Ross H, Lewis M. Preva-
lent left ventricular hypertrophy in the predialysis population:
identifying opportunities for intervention. Am J Kidney Dis
1996;27:347—54.
25] Tun A, Khan IA, Wattanasauwan N, Win MT, Hussain A, Hla TA,
Cherukuri VL, Vasavada BC, Sacchi TJ. Increased regional and
transmyocardial dispersion of ventricular repolarization in end-
stage renal disease. Can J Cardiol 1999;15:53—6.
26] Morales MA, Gremigni C, Dattolo P, Piacenti M, Cerrai T, Fazi A,
Pelosi G, Vergassola R, Maggiore Q. Signal-averaged ECG abnor-
malities in haemodialysis patients. Role of dialysis. Nephrol Dial
Transplant 1998;13:668—73.
27] Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall
WJ, Greenberg H, Case RB, Multicenter Automatic Deﬁbrillator
Implantation Trial-II Investigators. Relations among renal func-
tion, risk of sudden cardiac death, and beneﬁt of the implanted
cardiac deﬁbrillator in patients with ischemic left ventricular
dysfunction. Am J Cardiol 2006;98:485—90.
28] Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa
Y, Masuda I, Nakanishi K, Yoshimasa T, Hashimoto Y, Yam-
aguchi M, Hori R, Yasue H, Nakao K. Rapid ventricular induction
of brain natriuretic peptide gene expression in experimental
acute myocardial infarction. Circulation 1995;92:1558—64.
29] Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ,
Burnett JC, Rodeheffer RJ, Chesebro JH, Tazelaar HD. The
frequency of familial dilated cardiomyopathy in a series of
patients with idiopathic dilated cardiomyopathy. N Engl J Med
1992;326:77—82.
30] Muntoni F, Cau M, Ganau A, Congiu R, Arvedi G, Mateddu A,
Marrosu MG, Cianchetti C, Realdi G, Cao A, Melis MA. Brief
report: deletion of the dystrophin muscle-promoter region
6[
[4
associated with X-linked dilated cardiomyopathy. N Engl J Med
1993;329:921—5.
31] Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma
P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED,
Seidman JG, Seidman CE. Mutations in sarcomere protein
genes as a cause of dilated cardiomyopathy. N Engl J Med
2000;343:1688—96.
32] Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M,
Atherton J, Vidaillet Jr HJ, Spudich S, De Girolami U, Seidman
[H. Usuku et al.
JG, Seidman C, Muntoni F, Müehle G, Johnson W, et al. Missense
mutations in the rod domain of the lamin A/C gene as causes
of dilated cardiomyopathy and conduction-system disease. N
Engl J Med 1999;341:1715—24.33] D’Adamo P, Fassone L, Gedeon A, Janssen EA, Bione S, Bolhuis
PA, Barth PG, Wilson M, Haan E, Orstavik KH, Patton MA, Green
AJ, Zammarchi E, Donati MA, Toniolo D. The X-linked gene G4.5
is responsible for different infantile dilated cardiomyopathies.
Am J Hum Genet 1997;61:862—7.
